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Introduction
The pathogenesis of Psoriatic Arthritis (PsA) remains
poorly understood. The underlying chronic inflamma-
tory immune response is thought to be triggered by
unknown environmental factors and might arise due to
an impaired (innate) immune function by Dendritic
Cells (DCs) [1]. Anti-inflammatory CD163
+ type 2
macrophages (mf-2) are thought to have important
functions in restoring immune homeostasis during an
inflammatory response. Mf-2 are present in PsA syno-
vium at high numbers. Why the immune response in
PsA goes awry, despite the presence of these mf-2, is
still largely undetermined.
Aim
We aimed to determine whether mf-2 from PsA patients
have an aberrant phenotype thereby contributing to the
chronic inflammation occurring in PsA.
Patients and methods
Mf-2 from 12 healthy controls and 12 PsA patients were
analysed for their expression of various cell surface
r e c e p t o r sa sw e l la st h e i rc y t o k i n ep r o d u c t i o nw h e n
exposed to a range of bacteria and single Toll-Like
receptor (TLR) ligands. Differences between healthy
control and PsA mf-2 involved in suppressing DC func-
tion were determined by stimulation assays and mixed
leukocyte reactions.
Results
CCR5 was significantly increased on mf-2 from PsA
patients compared to healthy controls while the expres-
sion of CCR1, TLR2, TLR4 and CD14 was unaltered.
Further research revealed that PsA mf-2 secreted more
IL-6 upon incubation with heat-killed Escherichia coli
and E. coli lipopolysaccharide and were less efficient in
phagocytosing E. coli. The production of TNFa and IL-
10 was equivalent between the groups. The production
of cytokines was equal between PsA and healthy control
mf-2 upon the stimulation with M. tuberculosis, P. gingi-
valis or TLR2 or TLR7/8 ligands. In addition, PsA mf-2
were less capable of suppressing cytokine production by
DCs compared to mf-2 from healthy controls. Further
reflecting their disordered function was the finding that
in T cell assays PsA mf-2 are less capable of suppressing
DC induced IL-17 and TNFa production by T cells.
Conclusion
Anti-inflammatory CD163
+ mf-2 from PsA patients have
a clearly aberrant phenotype. This implicates mf-2 as an
important defective cell type in PsA facilitating chronic
inflammation instead of exerting their normal function
of restoring immune homeostasis.
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